D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile

Nature Communications
Sophie ValleixV Bellotti

Abstract

Apolipoprotein C-III deficiency provides cardiovascular protection, but apolipoprotein C-III is not known to be associated with human amyloidosis. Here we report a form of amyloidosis characterized by renal insufficiency caused by a new apolipoprotein C-III variant, D25V. Despite their uremic state, the D25V-carriers exhibit low triglyceride (TG) and apolipoprotein C-III levels, and low very-low-density lipoprotein (VLDL)/high high-density lipoprotein (HDL) profile. Amyloid fibrils comprise the D25V-variant only, showing that wild-type apolipoprotein C-III does not contribute to amyloid deposition in vivo. The mutation profoundly impacts helical structure stability of D25V-variant, which is remarkably fibrillogenic under physiological conditions in vitro producing typical amyloid fibrils in its lipid-free form. D25V apolipoprotein C-III is a new human amyloidogenic protein and the first conferring cardioprotection even in the unfavourable context of renal failure, extending the evidence for an important cardiovascular protective role of apolipoprotein C-III deficiency. Thus, fibrate therapy, which reduces hepatic APOC3 transcription, may delay amyloid deposition in affected patients.

References

Aug 23, 1990·The New England Journal of Medicine·P N HawkinsM B Pepys
Oct 31, 1988·Biochemical and Biophysical Research Communications·W C NicholsM D Benson
Feb 1, 1985·The Journal of Clinical Investigation·C S WangP Alaupovic
May 15, 1993·The Biochemical Journal·G LiuT Olivecrona
Jan 1, 1996·Methods in Enzymology·J GarnierB Robson
May 16, 2001·Current Opinion in Lipidology·N S Shachter
Feb 18, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Warren H CapellRobert H Eckel
Aug 16, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Anatol KontushM John Chapman
Oct 14, 2005·Journal of the American Society of Nephrology : JASN·Gina GregoriniFrancesco Scolari
Apr 11, 2008·Clinical Science·Esther M M OoiGerald F Watts
Apr 15, 2008·The Journal of Biological Chemistry·Chinthaka Saneth GangabadageSybren Sipke Wijmenga
Jun 3, 2008·Journal of Molecular Biology·Gian Gaetano TartagliaMichele Vendruscolo
Mar 6, 2009·Journal of Atherosclerosis and Thrombosis·Akio Kawakami, Masayuki Yoshida
Sep 5, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·Sandra LarredeWilfried Le Goff
Jun 29, 2010·Current Opinion in Lipidology·Anatol Kontush, M John Chapman
Aug 2, 2011·Journal of the American Society of Nephrology : JASN·Michael HolzerGunther Marsche
Sep 9, 2011·Kidney International·Sanjeev SethiAhmet Dogan
Nov 11, 2011·The New England Journal of Medicine·Oswald Quehenberger, Edward A Dennis
Feb 22, 2012·Nature Reviews. Nephrology·Murray Epstein, Nosratola D Vaziri
Jun 15, 2012·The New England Journal of Medicine·Sophie ValleixVittorio Bellotti
Jan 22, 2013·Proteomics·Simone NicolardiAndré M Deelder
Aug 28, 2013·Nature Reviews. Nephrology·Julian D Gillmore, Philip N Hawkins
Aug 30, 2013·The New England Journal of Medicine·Teresa CoelhoOle B Suhr
Oct 15, 2013·The Journal of Biological Chemistry·Mikael LarssonGunilla Olivecrona
Dec 18, 2013·Nature Communications·Ioanna TachmazidouEleftheria Zeggini
May 9, 2014·Biochemistry·Michel de MessieresJennifer C Lee
Jun 19, 2014·The New England Journal of Medicine·Jacy CrosbySekar Kathiresan

❮ Previous
Next ❯

Citations

Oct 21, 2016·Expert Review of Proteomics·Francesca Lavatelli, Giampaolo Merlini
Oct 25, 2016·Lipids in Health and Disease·Mengdie Luo, Daoquan Peng
Nov 26, 2016·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Jean D SipePer Westermark
Apr 13, 2017·Glycoconjugate Journal·Kazuchika Nishitsuji, Kenji Uchimura
Nov 23, 2016·Journal of Medical Genetics·Xianchi Li, Peiying Zhang
Dec 14, 2016·Annual Review of Pathology·Ahmet Dogan
Jan 25, 2018·International Journal of Molecular Sciences·Masahide YazakiNobuo Okumura
Jan 5, 2017·Journal of the American Society of Nephrology : JASN·Samih H NasrPaul J Kurtin
May 17, 2019·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Katerina C NastouVassiliki A Iconomidou
May 8, 2020·Journal of the Peripheral Nervous System : JPNS·Laura Obici, David Adams
May 25, 2020·Protoplasma·Nimisha GuptaSaima Wajid
Sep 16, 2020·Journal of Internal Medicine·E MuchtarM A Gertz
Feb 14, 2020·Transplantation·Avital Angel-Korman, Andrea Havasi
Oct 17, 2019·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Tomoaki MurakamiKazufumi Kawasako
May 11, 2019·International Journal of Molecular Sciences·Paraskevi L TsiolakiVassiliki A Iconomidou
Aug 31, 2020·Mayo Clinic Proceedings·Surendra DasariEllen D McPhail
Jan 5, 2021·Current Opinion in Lipidology·Natasha JerajAmanda J Berberich
Jun 16, 2019·Kidney International·Michèle ChabertAthina D Kalopissis
Apr 13, 2021·Mayo Clinic Proceedings·Michelle M HillEllen D McPhail
May 23, 2021·Clinics in Laboratory Medicine·David L Murray, Surendra Dasari
Jul 15, 2020·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Lara MeyerHélène François

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies
biopsy
atomic force microscopy
electrophoresis
NMR
circular dichroism
PCR
Protein assay

Software Mentioned

! Tandem
nmrPipe
ProteinPilot
Proteome
Analyst
Sequest
CCPN
Mascot
Scaffold

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

© 2022 Meta ULC. All rights reserved